AD is also known as atopic eczema. Credit: Assianir, courtesy of Oregon State University / Flickr (Creative Commons).

Technoderma Medicines has commenced dosing with its topical TDM-180935 ointment in healthy volunteer subjects in its Phase I study for Atopic Dermatitis (AD).

This is said to be the first trial in the AD programme and includes single dose, as well as multidose, escalation cohorts.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, randomised, vehicle-controlled, parallel group, dose escalation trial will assess the tolerability, safety, and pharmacokinetics of the ointment after topical administration in healthy male subjects.

Assessing the safety and pharmacokinetics of topical TDM-180935 are the objectives of the trial.

One study site in the US is participating in this trial at present under an open IND with the FDA.

See Also:

Technoderma Medicines chief medical officer Arthur Bertolino said: “We expect the current study to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase II AD study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We look forward to including patients with AD in the next clinical study and are encouraged by the selective advantages that may be provided by TDM-180935 as a potent JAK1/Tyk2 small molecule inhibitor.”

TDM–180935 is being developed as a topical drug to treat AD, which is also known as atopic eczema.

As a potent JAK1/Tyk2 small molecule inhibitor, the drug candidate is expected to offer advantages with regards to safety and efficacy against topical treatments that are currently available.

Technoderma Medicines CEO Zengquan Wang said: “We view the TDM-180935 AD programme as the second clinical anchor among our pipeline products for treatment of various dermatologic diseases.

“We are working to bring a third pipeline product into clinical testing later this year.”